Möchten Sie immer auf dem neuesten Stand bleiben?

SALT LAKE CITY, April 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the...

WEST HOLLYWOOD, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- OVERVIEW VisionWave Holdings, Inc. (Nasdaq: VWAV) today announced a signed non-binding term sheet for a strategic investment in...

ODIN WaveGuard EMF-shielding boxers: silver-fiber Faraday mesh claims, EMF exposure research context, pricing, and consumer considerations

Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Single Cell Sequencing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of System, End-user, Area of Application, and...

Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "FRP Tank Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's offering. ...

Monte Rosa Presents Preclinical Data at AACR 2026 on the Potential of its Cyclin E1 (CCNE1)-directed MGDs to Treat CCNE1-amplified Solid Tumors

Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Automotive Cybersecurity Market, till 2040: Distribution by Type of Component, Type of Form, Type of Security, Type of Vehicle, Application,...

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON,...

Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment in...